Holen Sie sich die Stockscreener-App
1.56
0.64%
-0.01
Handel nachbörslich:
1.56
Schlusskurs vom Vortag:
$1.57
Offen:
$1.59
24-Stunden-Volumen:
204.14K
Relative Volume:
0.70
Marktkapitalisierung:
$95.56M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-64.86M
KGV:
-1.3929
EPS:
-1.12
Netto-Cashflow:
$-55.66M
1W Leistung:
-9.83%
1M Leistung:
-10.86%
6M Leistung:
-54.39%
1J Leistung:
-52.58%
1-Tages-Spanne:
$1.53
$1.60
1-Wochen-Bereich:
$1.53
$1.7375
52-Wochen-Spanne:
$1.53
$5.09
Acumen Pharmaceuticals Inc Stock (ABOS) Company Profile
Firmenname
Acumen Pharmaceuticals Inc
Sektor
Branche
Telefon
925-368-8508
Adresse
427 PARK ST., CHARLOTTESVILLE
Vergleichen Sie ABOS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ABOS
Acumen Pharmaceuticals Inc
|
1.56 | 95.56M | 0 | -64.86M | -55.66M | -1.12 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.40 | 113.67B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
683.08 | 74.97B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
665.68 | 40.50B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
277.16 | 35.95B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
120.88 | 29.63B | 3.30B | -501.07M | 1.03B | -2.1146 |
Acumen Pharmaceuticals Inc Stock (ABOS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-07-26 | Eingeleitet | Citigroup | Buy |
| 2023-12-12 | Eingeleitet | Deutsche Bank | Buy |
| 2023-07-20 | Fortgesetzt | BofA Securities | Buy |
| 2023-05-18 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-07-15 | Eingeleitet | BTIG Research | Buy |
| 2022-06-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-01-21 | Hochstufung | BofA Securities | Neutral → Buy |
| 2021-07-26 | Eingeleitet | BofA Securities | Neutral |
| 2021-07-26 | Eingeleitet | Credit Suisse | Outperform |
| 2021-07-26 | Eingeleitet | Stifel | Buy |
| 2021-07-26 | Eingeleitet | UBS | Buy |
Alle ansehen
Acumen Pharmaceuticals Inc Aktie (ABOS) Neueste Nachrichten
Acumen Pharmaceuticals chief medical officer sells $5,118 in shares - MSN
Acumen Pharmaceuticals chief legal officer sells shares worth $5,434 - MSN
Acumen Pharmaceuticals COO Barton Russell sells shares worth $4,692 - MSN
Matt Zuga Sells 28,902 Shares of Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Stock - MarketBeat
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) CEO Daniel Joseph Oconnell Sells 12,619 Shares - MarketBeat
Acumen Pharmaceuticals CEO O'Connell sells shares worth $20,102 - MSN
Acumen Pharmaceuticals CFO sells shares totaling $56,619 - MSN
Analysts Set Expectations for ABOS FY2025 Earnings - Defense World
Acumen Pharmaceuticals CFO sells shares totaling $56,619 By Investing.com - Investing.com South Africa
Acumen Pharmaceuticals CEO O'Connell sells shares worth $20,102 By Investing.com - Investing.com Canada
Brokers Offer Predictions for ABOS FY2025 Earnings - MarketBeat
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Stock Holdings Lifted by Barclays PLC - Defense World
Short Interest in Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Expands By 9.1% - Defense World
Acumen stock touches 52-week low at $1.54 amid market challenges - MSN
Acumen stock touches 52-week low at $1.54 amid market challenges By Investing.com - Investing.com South Africa
Acumen Pharmaceuticals Announces Journal of Prevention of Alzheimer's Disease Publication of the Company's Phase 1 INTERCEPT-AD Study, Including Target Engagement, Dosing Regimen and Safety Findings - The Manila Times
Acumen Pharmaceuticals Announces Journal of Prevention of Alzheimer’s Disease Publication of - The Bakersfield Californian
Acumen's Alzheimer's Drug Shows Promise: Phase 1 Trial Reveals Strong Safety Profile, Plaque Reduction - StockTitan
Acumen Pharmaceuticals CFO Zuga Matt sells $24,366 in stock By Investing.com - Investing.com Australia
Acumen Pharmaceuticals' chief legal officer sells $20,505 in stock By Investing.com - Investing.com Australia
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Shares Purchased by Geode Capital Management LLC - Defense World
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Shares Bought by Barclays PLC - Defense World
Acumen Pharmaceuticals chief medical officer sells $20,046 in stock By Investing.com - Investing.com Nigeria
Acumen Pharmaceuticals COO Barton Russell sells $14,225 in stock - Investing.com India
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) COO Sells 7,636 Shares - MarketBeat
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Insider Eric Siemers Sells 10,859 Shares - MarketBeat
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) CEO Sells $87,911.52 in Stock - MarketBeat
Acumen Pharmaceuticals COO Barton Russell sells $14,225 in stock By Investing.com - Investing.com Nigeria
Acumen Pharmaceuticals’ chief legal officer sells $20,505 in stock By Investing.com - Investing.com Nigeria
Acumen Pharmaceuticals CEO sells shares worth $87,873 By Investing.com - Investing.com South Africa
Acumen Pharmaceuticals CFO Zuga Matt sells $24,366 in stock - Investing.com
Acumen Pharmaceuticals CEO sells shares worth $87,873 - Investing.com
Acumen Pharmaceuticals chief medical officer sells $20,046 in stock - Investing.com
Reviewing Acumen Pharmaceuticals (NASDAQ:ABOS) & argenx (NASDAQ:ARGX) - Defense World
State Street Corp Has $1.28 Million Position in Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) - Defense World
ABOS stock touches 52-week low at $1.71 amid market challenges - Investing.com Nigeria
ABOS stock touches 52-week low at $1.71 amid market challenges By Investing.com - Investing.com South Africa
Acumen stock touches 52-week low at $1.9 amid market challenges - Investing.com Australia
The Manufacturers Life Insurance Company Lowers Stake in Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) - Defense World
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Short Interest Update - MarketBeat
ABOS stock touches 52-week low at $2.08 amid market challenges - Investing.com Australia
Finanzdaten der Acumen Pharmaceuticals Inc-Aktie (ABOS)
Umsatz
Nettogewinn
Free Cashflow
ENV
5.49%
0.79%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):